HRP20050933A2 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
HRP20050933A2
HRP20050933A2 HR20050933A HRP20050933A HRP20050933A2 HR P20050933 A2 HRP20050933 A2 HR P20050933A2 HR 20050933 A HR20050933 A HR 20050933A HR P20050933 A HRP20050933 A HR P20050933A HR P20050933 A2 HRP20050933 A2 HR P20050933A2
Authority
HR
Croatia
Prior art keywords
organic compounds
compounds
zwitterions
muscarinic
receptor
Prior art date
Application number
HR20050933A
Other languages
English (en)
Croatian (hr)
Inventor
Paul Collingwood Stephen
Cox Brian
Baettig Urs
Bhalay Gurdip
James Devereux Nicholas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33420896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050933(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0324887A external-priority patent/GB0324887D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20050933A2 publication Critical patent/HRP20050933A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20050933A 2003-05-02 2004-04-30 Organic compounds HRP20050933A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0310232 2003-05-02
GB0324887A GB0324887D0 (en) 2003-10-24 2003-10-24 Organic compounds
PCT/EP2004/004605 WO2004096800A2 (fr) 2003-05-02 2004-04-30 Composes organiques

Publications (1)

Publication Number Publication Date
HRP20050933A2 true HRP20050933A2 (en) 2006-12-31

Family

ID=33420896

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050933A HRP20050933A2 (en) 2003-05-02 2004-04-30 Organic compounds

Country Status (31)

Country Link
US (2) US20070060563A1 (fr)
EP (1) EP1631569B1 (fr)
JP (1) JP4416786B2 (fr)
KR (1) KR100896544B1 (fr)
AR (1) AR044134A1 (fr)
AT (1) ATE440840T1 (fr)
AU (1) AU2004234069B2 (fr)
BR (1) BRPI0410238A (fr)
CA (1) CA2523436C (fr)
CL (1) CL2004000918A1 (fr)
CO (1) CO5700782A2 (fr)
CY (1) CY1109655T1 (fr)
DE (1) DE602004022805D1 (fr)
DK (1) DK1631569T3 (fr)
EC (1) ECSP056134A (fr)
ES (1) ES2331185T3 (fr)
HR (1) HRP20050933A2 (fr)
IL (1) IL171591A (fr)
IS (1) IS2746B (fr)
MA (1) MA27775A1 (fr)
MX (1) MXPA05011739A (fr)
MY (1) MY142652A (fr)
NO (1) NO20055688L (fr)
NZ (1) NZ542995A (fr)
PE (1) PE20050465A1 (fr)
PL (1) PL1631569T3 (fr)
PT (1) PT1631569E (fr)
RU (1) RU2363700C2 (fr)
SI (1) SI1631569T1 (fr)
TW (1) TWI340139B (fr)
WO (1) WO2004096800A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1900737A1 (fr) * 2006-08-31 2008-03-19 Novartis AG Polymorphe de (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide
EP1894568A1 (fr) * 2006-08-31 2008-03-05 Novartis AG Composées pharmaceutiques destinées au traitement des maladies inflammatoires ou obstructives des bronches
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
ATE555111T1 (de) * 2006-12-19 2012-05-15 Astrazeneca Ab Chinuclidinol-derivate als muscarinrezeptor- antagonisten
EP1950196A1 (fr) * 2007-01-29 2008-07-30 Boehringer Ingelheim Pharma GmbH & Co. KG Procédé de fabrication d'hexafluorophosphates d'ammonium
JP5656288B2 (ja) * 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
US8017617B2 (en) * 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
BRPI0912657A2 (pt) * 2008-05-13 2016-01-26 Astrazeneca Ab produto farmacêutico compreendendo um antagonista de receptor muscarínico e um agonista beta2-adrenorreceptor
EA017627B1 (ru) * 2008-05-13 2013-01-30 Астразенека Аб Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
GB0811100D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination
WO2009153536A1 (fr) * 2008-06-17 2009-12-23 Argenta Discovery Limited Dérivés de 1-aza-bicyclo [2.2.2] octane utiles en tant qu’antagonistes des récepteurs muscariniques
BR112012032332A2 (pt) * 2010-06-22 2016-11-08 Chiesi Farma Spa composto, uso de um composto, composição farmacêutica, combinação de um composto e dispositivo
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
BR112014013179A2 (pt) * 2011-12-30 2017-06-13 Chiesi Farm Spa compostos, combinação de um composto, composição farmacêutica e usos de um composto
WO2013166413A2 (fr) * 2012-05-03 2013-11-07 Saint Louis College Of Pharmacy Compositions et procédés pour augmenter des peptides neurotrophiques
TWI647227B (zh) 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽
CZ306791B6 (cs) 2013-10-29 2017-07-12 Zentiva, K.S. Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
PL3111978T3 (pl) 2015-07-03 2022-01-24 Novartis Ag Inhalator przystosowany do odczytu informacji przechowywanych w środkach przechowywania danych pojemnika

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
DK534178A (da) * 1977-12-16 1979-06-17 Interx Research Corp Anticholinerge midler med sektrtionshaemmende virkning
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP1302458A4 (fr) * 2000-07-11 2005-10-19 Banyu Pharma Co Ltd Derives d'ester
DE60121813T2 (de) * 2000-12-28 2007-09-20 Almirall Ag Neue chinuclidinderivate und medizinische zusammensetzungen, die diese verbindungen enthalten
JP4505227B2 (ja) * 2001-12-20 2010-07-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1900737A1 (fr) * 2006-08-31 2008-03-19 Novartis AG Polymorphe de (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide

Also Published As

Publication number Publication date
PT1631569E (pt) 2009-11-26
RU2005137360A (ru) 2006-07-27
US20070060563A1 (en) 2007-03-15
AR044134A1 (es) 2005-08-24
MY142652A (en) 2010-12-15
AU2004234069A1 (en) 2004-11-11
US20100041887A1 (en) 2010-02-18
IL171591A (en) 2010-11-30
CA2523436A1 (fr) 2004-11-11
EP1631569B1 (fr) 2009-08-26
JP4416786B2 (ja) 2010-02-17
ECSP056134A (es) 2006-04-19
TWI340139B (en) 2011-04-11
CY1109655T1 (el) 2014-08-13
IS8158A (is) 2005-11-30
KR20060015572A (ko) 2006-02-17
JP2006525267A (ja) 2006-11-09
AU2004234069B2 (en) 2008-02-21
PL1631569T3 (pl) 2010-02-26
TW200505920A (en) 2005-02-16
BRPI0410238A (pt) 2006-05-16
CA2523436C (fr) 2011-11-01
NO20055688D0 (no) 2005-12-01
CO5700782A2 (es) 2006-11-30
US8168654B2 (en) 2012-05-01
CL2004000918A1 (es) 2005-02-11
NZ542995A (en) 2009-02-28
ES2331185T3 (es) 2009-12-23
SI1631569T1 (sl) 2010-01-29
KR100896544B1 (ko) 2009-05-07
WO2004096800A2 (fr) 2004-11-11
HK1087704A1 (en) 2006-10-20
RU2363700C2 (ru) 2009-08-10
NO20055688L (no) 2006-01-09
DK1631569T3 (da) 2009-11-23
IS2746B (is) 2011-08-15
EP1631569A2 (fr) 2006-03-08
ATE440840T1 (de) 2009-09-15
MXPA05011739A (es) 2006-01-26
WO2004096800A3 (fr) 2005-01-06
PE20050465A1 (es) 2005-07-18
DE602004022805D1 (de) 2009-10-08
MA27775A1 (fr) 2006-02-01

Similar Documents

Publication Publication Date Title
HRP20050933A2 (en) Organic compounds
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200519106A (en) Organic compounds
SE0401971D0 (sv) Piperidne derivatives
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
WO2007084595A3 (fr) Benzènesulfonyle-chromane, thiochromane, tétrahydronaphthalène et inhibiteurs de la gamma secrétase associés
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
SE0403171D0 (sv) New compounds
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
SE0401970D0 (sv) Novel compounds
ATE449069T1 (de) Aminopropanolderivate
SE0303541D0 (sv) New compounds
BRPI0519292A2 (pt) compostos orgÂnicos
WO2009055629A3 (fr) Antagonistes trpv1
MXPA05013823A (es) Derivados de pirrolidinio y piperidino como ligandos para el receptor m3 muscarinico.
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
SE0303280D0 (sv) Novel compounds
ATE409179T1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
SE0302755D0 (sv) Novel compounds

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110423

Year of fee payment: 8

OBST Application withdrawn